Oral vinorelbine (Navelbine) in the treatment of advanced non-small cell lung cancer: A preliminary report

E. E. Vokes, R. Rosenberg, M. Jahanzeb, J. Craig, Richard J. Gralla, C. Belani, S. Jones, J. Bigley, J. Hohneker, Gralla, O'Rourke, Crawford, Tuttle, Viallet, Moinpour

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Medicament, Paris, France) is a novel semisynthetic vinca alkaloid with antitumor activity in non-small cell lung cancer. An oral preparation of this drug is under investigation and was tested in a multicenter phase II study in patients with stage IV measurable or evaluable non-small cell lung cancer. The initial vinorelbine dose was 100 mg/m2/wk (80 mg/m2/wk for patients with prior radiotherapy). Following an initial 37% incidence of grade 3 or 4 neutropenia, the dose was reduced by 40 mg/dose. Nausea, vomiting, diarrhea, and mucositis were other frequently observed toxicities. A preliminary analysis indicated a response rate of 14%, suggesting activity of this drug when administered orally.

Original languageEnglish (US)
Pages (from-to)35-41
Number of pages7
JournalSeminars in Oncology
Volume21
Issue number5 SUPPL. 10
StatePublished - 1994
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Vinca Alkaloids
Drug Compounding
Mucositis
Paris
Neutropenia
Nausea
France
Vomiting
Diarrhea
Radiotherapy
Therapeutics
Incidence
Research
Pharmaceutical Preparations
vinorelbine

ASJC Scopus subject areas

  • Oncology

Cite this

Vokes, E. E., Rosenberg, R., Jahanzeb, M., Craig, J., Gralla, R. J., Belani, C., ... Moinpour (1994). Oral vinorelbine (Navelbine) in the treatment of advanced non-small cell lung cancer: A preliminary report. Seminars in Oncology, 21(5 SUPPL. 10), 35-41.

Oral vinorelbine (Navelbine) in the treatment of advanced non-small cell lung cancer : A preliminary report. / Vokes, E. E.; Rosenberg, R.; Jahanzeb, M.; Craig, J.; Gralla, Richard J.; Belani, C.; Jones, S.; Bigley, J.; Hohneker, J.; Gralla; O'Rourke; Crawford; Tuttle; Viallet; Moinpour.

In: Seminars in Oncology, Vol. 21, No. 5 SUPPL. 10, 1994, p. 35-41.

Research output: Contribution to journalArticle

Vokes, EE, Rosenberg, R, Jahanzeb, M, Craig, J, Gralla, RJ, Belani, C, Jones, S, Bigley, J, Hohneker, J, Gralla, O'Rourke, Crawford, Tuttle, Viallet & Moinpour 1994, 'Oral vinorelbine (Navelbine) in the treatment of advanced non-small cell lung cancer: A preliminary report', Seminars in Oncology, vol. 21, no. 5 SUPPL. 10, pp. 35-41.
Vokes EE, Rosenberg R, Jahanzeb M, Craig J, Gralla RJ, Belani C et al. Oral vinorelbine (Navelbine) in the treatment of advanced non-small cell lung cancer: A preliminary report. Seminars in Oncology. 1994;21(5 SUPPL. 10):35-41.
Vokes, E. E. ; Rosenberg, R. ; Jahanzeb, M. ; Craig, J. ; Gralla, Richard J. ; Belani, C. ; Jones, S. ; Bigley, J. ; Hohneker, J. ; Gralla ; O'Rourke ; Crawford ; Tuttle ; Viallet ; Moinpour. / Oral vinorelbine (Navelbine) in the treatment of advanced non-small cell lung cancer : A preliminary report. In: Seminars in Oncology. 1994 ; Vol. 21, No. 5 SUPPL. 10. pp. 35-41.
@article{7ce4e31532834cc1934fd036076b1fb2,
title = "Oral vinorelbine (Navelbine) in the treatment of advanced non-small cell lung cancer: A preliminary report",
abstract = "Vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Medicament, Paris, France) is a novel semisynthetic vinca alkaloid with antitumor activity in non-small cell lung cancer. An oral preparation of this drug is under investigation and was tested in a multicenter phase II study in patients with stage IV measurable or evaluable non-small cell lung cancer. The initial vinorelbine dose was 100 mg/m2/wk (80 mg/m2/wk for patients with prior radiotherapy). Following an initial 37{\%} incidence of grade 3 or 4 neutropenia, the dose was reduced by 40 mg/dose. Nausea, vomiting, diarrhea, and mucositis were other frequently observed toxicities. A preliminary analysis indicated a response rate of 14{\%}, suggesting activity of this drug when administered orally.",
author = "Vokes, {E. E.} and R. Rosenberg and M. Jahanzeb and J. Craig and Gralla, {Richard J.} and C. Belani and S. Jones and J. Bigley and J. Hohneker and Gralla and O'Rourke and Crawford and Tuttle and Viallet and Moinpour",
year = "1994",
language = "English (US)",
volume = "21",
pages = "35--41",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "5 SUPPL. 10",

}

TY - JOUR

T1 - Oral vinorelbine (Navelbine) in the treatment of advanced non-small cell lung cancer

T2 - A preliminary report

AU - Vokes, E. E.

AU - Rosenberg, R.

AU - Jahanzeb, M.

AU - Craig, J.

AU - Gralla, Richard J.

AU - Belani, C.

AU - Jones, S.

AU - Bigley, J.

AU - Hohneker, J.

AU - Gralla,

AU - O'Rourke,

AU - Crawford,

AU - Tuttle,

AU - Viallet,

AU - Moinpour,

PY - 1994

Y1 - 1994

N2 - Vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Medicament, Paris, France) is a novel semisynthetic vinca alkaloid with antitumor activity in non-small cell lung cancer. An oral preparation of this drug is under investigation and was tested in a multicenter phase II study in patients with stage IV measurable or evaluable non-small cell lung cancer. The initial vinorelbine dose was 100 mg/m2/wk (80 mg/m2/wk for patients with prior radiotherapy). Following an initial 37% incidence of grade 3 or 4 neutropenia, the dose was reduced by 40 mg/dose. Nausea, vomiting, diarrhea, and mucositis were other frequently observed toxicities. A preliminary analysis indicated a response rate of 14%, suggesting activity of this drug when administered orally.

AB - Vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Medicament, Paris, France) is a novel semisynthetic vinca alkaloid with antitumor activity in non-small cell lung cancer. An oral preparation of this drug is under investigation and was tested in a multicenter phase II study in patients with stage IV measurable or evaluable non-small cell lung cancer. The initial vinorelbine dose was 100 mg/m2/wk (80 mg/m2/wk for patients with prior radiotherapy). Following an initial 37% incidence of grade 3 or 4 neutropenia, the dose was reduced by 40 mg/dose. Nausea, vomiting, diarrhea, and mucositis were other frequently observed toxicities. A preliminary analysis indicated a response rate of 14%, suggesting activity of this drug when administered orally.

UR - http://www.scopus.com/inward/record.url?scp=0028105087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028105087&partnerID=8YFLogxK

M3 - Article

C2 - 7973767

AN - SCOPUS:0028105087

VL - 21

SP - 35

EP - 41

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 5 SUPPL. 10

ER -